Terms: = Skin cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS AND Clinical Outcome
4 results:
1. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract] [Full Text] [Related]
2. Superficial low-grade fibromyxoid sarcoma.
Ronen S; Ko JS; Rubin BP; Kilpatrick SE; Wang WL; Lazar AJ; Goldblum JR; Billings SD
J Cutan Pathol; 2023 Feb; 50(2):147-154. PubMed ID: 36074249
[TBL] [Abstract] [Full Text] [Related]
3. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
Mencía-Gutiérrez E; Gutiérrez-Díaz E; Salamanca J; Martínez-González MA
Int J Dermatol; 2006 Jun; 45(6):766-9. PubMed ID: 16796648
[TBL] [Abstract] [Full Text] [Related]
4. What is CD4+CD56+ malignancy and how should it be treated?
Reimer P; Rüdiger T; Kraemer D; Kunzmann V; Weissinger F; Zettl A; Konrad Müller-Hermelink H; Wilhelm M
Bone Marrow Transplant; 2003 Oct; 32(7):637-46. PubMed ID: 13130309
[TBL] [Abstract] [Full Text] [Related]
